MarketPulse

Medicare coverage

3 articles
The Motley FoolThe Motley Fool··Lee Samaha

Grail Stock Surges on Analyst Optimism Despite Cancer Test Setback

Grail stock jumped 11.4% as Wall Street analysts see upside in its cancer detection test despite February trial disappointment.
GRALFDA approvalcancer detection
BenzingaBenzinga··Vandana Singh

Novo Nordisk Cuts GLP-1 Drug Prices 50% Amid Clinical Setbacks

Novo Nordisk cuts GLP-1 drug prices 50% to $675/month starting 2027 amid clinical setbacks and competitive pressure from rivals like Eli Lilly.
LLYNVOclinical trialprice reduction
BenzingaBenzinga··Namrata Sen

Eli Lilly Stockpiles $1.5B in Experimental Weight-Loss Drug Ahead of FDA Review

Eli Lilly stockpiles $1.5B of experimental weight-loss drug orforglipron ahead of expected April FDA approval decision, signaling management confidence.
LLYNVOFDA approvalpharmaceutical competition